Compare PAAS & WST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PAAS | WST |
|---|---|---|
| Founded | 1994 | 1923 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.0B | 20.2B |
| IPO Year | 1995 | N/A |
| Metric | PAAS | WST |
|---|---|---|
| Price | $54.97 | $260.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 7 |
| Target Price | $47.00 | ★ $338.00 |
| AVG Volume (30 Days) | ★ 6.2M | 706.4K |
| Earning Date | 02-18-2026 | 02-12-2026 |
| Dividend Yield | ★ 0.83% | 0.34% |
| EPS Growth | N/A | ★ 0.17 |
| EPS | 1.73 | ★ 6.75 |
| Revenue | ★ $3,254,800,000.00 | $3,017,900,000.00 |
| Revenue This Year | $27.28 | $6.97 |
| Revenue Next Year | $21.01 | $6.27 |
| P/E Ratio | ★ $36.75 | $38.48 |
| Revenue Growth | ★ 21.75 | 4.92 |
| 52 Week Low | $20.55 | $187.43 |
| 52 Week High | $57.20 | $348.90 |
| Indicator | PAAS | WST |
|---|---|---|
| Relative Strength Index (RSI) | 61.35 | 37.75 |
| Support Level | $51.14 | $267.82 |
| Resistance Level | $57.19 | $281.55 |
| Average True Range (ATR) | 1.96 | 8.88 |
| MACD | -0.21 | -1.13 |
| Stochastic Oscillator | 71.33 | 1.84 |
Pan American Silver Corp is a mining company principally engaged in the operation and development of, and exploration for, silver and gold-producing properties and assets. The company's principal products are silver and gold, although it also produces and sells zinc, lead, and copper. Its operating mines comprise La Colorada, Dolores, Huaron, Morococha, Shahuindo, La Arena, Timmins West, Bell Creek, Manantial Espejo, and San Vicente mines.
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.